Alleviation of nickel toxicity in wheat (Triticum aestivum L.) seedlings by selenium supplementation

Hydroponically grown wheat seedlings were treated with 50 μM N i and/or 15 μM Se. After a 7-day culture period, their growth parameters, N i, Se, F e, and M g contents, electrolyte leakage, photosynthetic pigment concentrations, and photochemical activity of photosystem II were determined. Exposure of wheat seedlings to N i alone resulted in reduction in the total shoot and root lengths, by 22% and 50%, respectively. Addition of Se to the N i-containing medium significantly improved the growth of these organs, compared to the seedlings subjected to N i alone. Application of Se decreased the accumulation of N i in shoots and roots and partially alleviated the N i-induced decrease in F e and M g concentations in shoots. Electrolyte leakage increased in response to N i stress, but in shoots it was diminished by Se supplementation. Exposure to N i led to a decrease in chlorophyll a and b contents and enhancement of chlorophyll a/b ratio, but did not influence the concentration of carotenoids. Enrichment of the N i-containing medium with Se significantly increased chlorophyll b content, compared to the seedlings treated with N i alone. Photochemical activity, estimated in terms of the maximum quantum yield of photosystem II, decreased in response to N i treatment but was significantly improved by simultaneous addition of Se. Results of our study suggest that alleviation of N i toxicity in wheat seedlings by Se supplementation may be related to limitation of N i uptake

High-Performance Lightweight HLS Generator Module of Normally Distributed Random Numbers in FPGAs

This paper focuses on the problem of high-performance streaming random number generation in the range of uniform and normal distributions in FPGAs. Our work is focused on lightweight implementation, suitable for a wide range of FPGAs. First, we review the existing types of random generation modules. Next, in this paper we present the construction of the designed generator. We divide it into two sections: Stream Uniform Numbers Generator Implementation and Cumulative Distribution-Based Stream Gaussian Generator. Each design step was verified in the scope of the quality of the output data, especially regarding the produced distributions. The results obtained are compared with existing solutions. We mainly consider resource utilization and throughput. We also add our quality factor, which is an effective utilization of FPGAs. Despite quality results, our modules were implemented using a high-level synthesis language (C/C++), contrary to typical hardware description level (HDL) approaches. It provides the opportunity to implement the proposed algorithms on CPUs. It was tested with positive results, thus highlighting the versatility of the solution that is unavailable in terms of HDL implementations. Our designed generators were confirmed to stand out for their satisfactory performance while occupying low logical resources

The cosmic ray detector for the NICA collider

Multi-Purpose Detector (MPD) is a main part of a new Ion Collider fAcility (NICA) located in Dubna, Russia. To increase MPD functionality, it was proposed to add an additional muon trigger system for off-beam calibration of the MPD sub-detectors and for rejection of cosmic ray background during experiments. The system could also be very useful for astrophysical observations of cosmic showers initiated by high energy primary particles. This article describes the main goals of MCORD detector and the early stage of MCORD design, based on plastic scintillators with silicon photomultiplier photodetectors (SiPM) for scintillation readout and electronic system based on MicroTCA standard

The cosmic ray detector for the NICA collider

Multi-Purpose Detector (MPD) is a main part of a new Ion Collider fAcility (NICA) located in Dubna, Russia. To increase MPD functionality, it was proposed to add an additional muon trigger system for off-beam calibration of the MPD sub-detectors and for rejection of cosmic ray background during experiments. The system could also be very useful for astrophysical observations of cosmic showers initiated by high energy primary particles. This article describes the main goals of MCORD detector and the early stage of MCORD design, based on plastic scintillators with silicon photomultiplier photodetectors (SiPM) for scintillation readout and electronic system based on MicroTCA standard

Intravenous versus subcutaneous immunoglobulin \u2013 Authors' reply

Reply to comment for Intravenous subcutaneous immunoglobuli

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

Background Complement is likely to have a role in refractory generalised myasthenia gravis, but no approved therapies specifically target this system. Results from a phase 2 study suggested that eculizumab, a terminal complement inhibitor, produced clinically meaningful improvements in patients with anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis. We further assessed the efficacy and safety of eculizumab in this patient population in a phase 3 trial. Methods We did a phase 3, randomised, double-blind, placebo-controlled, multicentre study (REGAIN) in 76 hospitals and specialised clinics in 17 countries across North America, Latin America, Europe, and Asia. Eligible patients were aged at least 18 years, with a Myasthenia Gravis-Activities of Daily Living (MG-ADL) score of 6 or more, Myasthenia Gravis Foundation of America (MGFA) class II\ue2\u80\u93IV disease, vaccination against Neisseria meningitides, and previous treatment with at least two immunosuppressive therapies or one immunosuppressive therapy and chronic intravenous immunoglobulin or plasma exchange for 12 months without symptom control. Patients with a history of thymoma or thymic neoplasms, thymectomy within 12 months before screening, or use of intravenous immunoglobulin or plasma exchange within 4 weeks before randomisation, or rituximab within 6 months before screening, were excluded. We randomly assigned participants (1:1) to either intravenous eculizumab or intravenous matched placebo for 26 weeks. Dosing for eculizumab was 900 mg on day 1 and at weeks 1, 2, and 3; 1200 mg at week 4; and 1200 mg given every second week thereafter as maintenance dosing. Randomisation was done centrally with an interactive voice or web-response system with patients stratified to one of four groups based on MGFA disease classification. Where possible, patients were maintained on existing myasthenia gravis therapies and rescue medication was allowed at the study physician's discretion. Patients, investigators, staff, and outcome assessors were masked to treatment assignment. The primary efficacy endpoint was the change from baseline to week 26 in MG-ADL total score measured by worst-rank ANCOVA. The efficacy population set was defined as all patients randomly assigned to treatment groups who received at least one dose of study drug, had a valid baseline MG-ADL assessment, and at least one post-baseline MG-ADL assessment. The safety analyses included all randomly assigned patients who received eculizumab or placebo. This trial is registered with ClinicalTrials.gov, number NCT01997229. Findings Between April 30, 2014, and Feb 19, 2016, we randomly assigned and treated 125 patients, 62 with eculizumab and 63 with placebo. The primary analysis showed no significant difference between eculizumab and placebo (least-squares mean rank 56\uc2\ub76 [SEM 4\uc2\ub75] vs 68\uc2\ub73 [4\uc2\ub75]; rank-based treatment difference \ue2\u88\u9211\uc2\ub77, 95% CI \ue2\u88\u9224\uc2\ub73 to 0\uc2\ub796; p=0\uc2\ub70698). No deaths or cases of meningococcal infection occurred during the study. The most common adverse events in both groups were headache and upper respiratory tract infection (ten [16%] for both events in the eculizumab group and 12 [19%] for both in the placebo group). Myasthenia gravis exacerbations were reported by six (10%) patients in the eculizumab group and 15 (24%) in the placebo group. Six (10%) patients in the eculizumab group and 12 (19%) in the placebo group required rescue therapy. Interpretation The change in the MG-ADL score was not statistically significant between eculizumab and placebo, as measured by the worst-rank analysis. Eculizumab was well tolerated. The use of a worst-rank analytical approach proved to be an important limitation of this study since the secondary and sensitivity analyses results were inconsistent with the primary endpoint result; further research into the role of complement is needed. Funding Alexion Pharmaceuticals

Energy Dependence of the Transverse Momentum Distributions of Charged Particles in pp Collisions Measured by ALICE

Differential cross sections of charged particles in inelastic pp collisions as a function of p_T have been measured at $\sqrt{s}$ = 0.9, 2.76 and 7 TeV at the LHC. The $p_T$ spectra are compared to NLO-pQCD calculations. Though the differential cross section for an individual $\sqrt{s}$ cannot be described by NLO-pQCD, the relative increase of cross section with sqrt(s) is in agreement with NLO-pQCD. Based on these measurements and observations, procedures are discussed to construct pp reference spectra at $\sqrt{s}$ = 2.76 and 5.02 TeV up to $p_T$ = 50 GeV/c as required for the calculation of the nuclear modification factor in nucleus-nucleus and proton-nucleus collisions